Laid Bare By Coronavirus: China Starts To Fix A Huge But Fragile Health System
Changing Drug Access, Pricing, Coverage In Public Health Crisis
Executive Summary
Shocking tales of people infected with the new coronavirus but who couldn’t get timely treatment due to lack of any or appropriate insurance have prompted fundamental changes in China’s health care system, with the government now trying to fix some notorious issues including payment before treatment.
You may also be interested in...
Q1 China Preview: Digital Health, Volume Pricing Loom Large For J&J, Sanofi
While many pharma firms rush to develop treatments or vaccines for the pandemic, some are quietly betting on digital health tools to bolster their business in post-coronavirus China.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Chinese Language Podcast: BIOSECURE Act, US PD-1 Approval, ADC Updates
Guest speaker and lawyer Kevin Duan joins Brian Yang and Dexter Yan to discuss the planned US BIOSECURE Act, the US approval of BeiGene's anti-PD-1 drug and the latest antibody-drug conjugates in development at Chinese pharma firms.